CN112841637A - 一种辅助降血糖的营养素组合物 - Google Patents
一种辅助降血糖的营养素组合物 Download PDFInfo
- Publication number
- CN112841637A CN112841637A CN202110343293.3A CN202110343293A CN112841637A CN 112841637 A CN112841637 A CN 112841637A CN 202110343293 A CN202110343293 A CN 202110343293A CN 112841637 A CN112841637 A CN 112841637A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- dietary fiber
- group
- nutrient composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 91
- 210000004369 blood Anatomy 0.000 title claims abstract description 51
- 239000008280 blood Substances 0.000 title claims abstract description 51
- 230000001603 reducing effect Effects 0.000 title claims abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 11
- 239000011707 mineral Substances 0.000 claims abstract description 11
- 235000018102 proteins Nutrition 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 229940088594 vitamin Drugs 0.000 claims abstract description 11
- 229930003231 vitamin Natural products 0.000 claims abstract description 11
- 235000013343 vitamin Nutrition 0.000 claims abstract description 11
- 239000011782 vitamin Substances 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 210000004153 islets of langerhan Anatomy 0.000 claims description 14
- 229930003270 Vitamin B Natural products 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 239000011720 vitamin B Substances 0.000 claims description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 235000019197 fats Nutrition 0.000 claims description 10
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 10
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 8
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims description 8
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 8
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 7
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 7
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 7
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 7
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 7
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 7
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 7
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 7
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 7
- 229920002414 procyanidin Polymers 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229960005559 sulforaphane Drugs 0.000 claims description 5
- 235000015487 sulforaphane Nutrition 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 235000020238 sunflower seed Nutrition 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 56
- 235000016709 nutrition Nutrition 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 230000035764 nutrition Effects 0.000 abstract description 10
- 239000013589 supplement Substances 0.000 abstract description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 3
- 230000008816 organ damage Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 69
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000013312 flour Nutrition 0.000 description 8
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 108091005995 glycated hemoglobin Proteins 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000009179 medical nutrition therapy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940071440 soy protein isolate Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 235000021069 high fat-high sugar diet Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033603 Pancreatic atrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000003904 glomerular cell Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种辅助降血糖的营养素组合物,其特征在于,所述组合物由以下重量百分比的成分组成:蛋白质50‑60%,碳水化合物10‑20%,脂肪0.5‑1.5%,膳食纤维20‑30%,维生素、矿物质及其他营养素3‑5%。本发明的营养素组合物能够改善糖代谢,补充糖尿病人所需营养,辅助常规的药物治疗,同时能够减轻器官损伤。
Description
技术领域
本发明涉及功能食品领域,尤其涉及一种辅助降血糖的营养素组合物。
背景技术
糖尿病患者临床表现为由胰岛功能衰退而导致的糖代谢功能紊乱及持续高血糖症状,同时,糖尿病会因其临床症状而导致很多的并发症,严重威胁患者的身体健康。
Ⅱ型糖尿病是糖尿病中最常见的一种,胰岛素抵抗是Ⅱ型糖尿病发展过程中的关键阶段,也是病因学中的一个重要组成部分。中国糖尿病医学营养治疗指南(2013)指出营养是糖尿病治疗的基础,糖尿病患者存在胰岛素抵抗或胰岛素分泌不足,胰岛功能的康复需要良好的机体内环境和充足的营养支持。而糖尿病患者在糖尿病状态下的代谢紊乱很容易导致体内营养水平的异常,除血糖血脂异常改变外,也容易继发感染和微血管并发症,且需饮食控制及药物治疗,体内维生素和矿物质的营养状况会受到影响。已有大量研究表明糖尿病患者体内普遍存在营养缺乏症状。对糖尿病人进行合理的营养补充,不仅可以改变糖尿病患者的营养状况,还可以达到改善预后、提高生命质量的目的。
医学营养治疗(Medical Nutrition Therapy,MNT)是临床上对特定疾病的营养障碍采取的特定营养干预措施,包括对患者进行个体化营养评估、制定相应的营养干预计划并在一定时期内实施并监测。20世纪70年代美国糖尿病学会(ADA)首次颁布“糖尿病患者营养与饮食推荐原则”。20年后ADA 提出MNT的概念,并与药物治疗相提并论。此外,美国临床内分泌医师协会、国际糖尿病联盟、加拿大糖尿病学会、欧洲糖尿病研究学会也一致推荐MNT作为糖尿病的重要治疗措施。
纵观国内外关于营养素和糖尿病的研究发现,大部分的研究都集中在单一营养素对糖尿病的影响上,然而在糖尿病状态下的代谢紊乱会导致糖尿病人体内各种营养素平衡异常,这无疑限制了糖尿病状态下胰岛β细胞增殖及生理功能的正常恢复,以至于应用单一营养素并不能最终降低或阻止糖尿病动物的高体内血糖水平。另外我国糖尿病患者膳食结构仍存在不合理状况,在治疗期间,许多患者的营养状况进一步发生恶化。营养不良会损害机体自身的防御机制,降低对感染的抵抗力,从而使康复减慢,病死率增加,因此糖尿病患者需要补充更全面更均衡的营养。
发明内容
为解决上述技术问题,本发明提供了一种辅助降血糖的营养素组合物,能够改善糖代谢,补充糖尿病人所需营养,辅助常规的药物治疗,同时能够减轻器官损伤,作为其他相关产品开发及应用的借鉴来源。
本发明的一种辅助降血糖的营养素组合物,组合物由以下重量百分比的成分组成:蛋白质50-60%,碳水化合物10-20%,脂肪0.5-1.5%,膳食纤维 20-30%,维生素、矿物质及其他营养素3-5%;其中,膳食纤维为不溶性膳食纤维、可溶性膳食纤维和低聚果糖的组合;维生素为维生素A、维生素E、维生素B1、维生素B2、维生素C、叶酸、泛酸、维生素D3、β-胡萝卜素、维生素B6和维生素B12的组合;矿物质为镁、硒、铬、锰、铜、钙、铁和锌的组合;其他营养素为松果菊苷、总黄酮苷、原花青素、芍药苷、萝卜硫苷、甘草酸、肌醇和生物素的组合。
本发明营养素组合物中,蛋白质的重量为组合物总重量的1/2及以上,可使患者食欲减退、饱腹感增强,同时考虑高血糖会增加机体蛋白质的转换等因素,蛋白质含量不宜过高。因此该营养素组合物的摄入并不增加血糖浓度,也不减慢糖类的吸收,但可增加血清胰岛素反应;
脂肪为中短链不饱和脂肪酸,能够降低炎症因子,增加胰岛素的敏感性, n-3型的长链多不饱和脂肪酸的作用与其相反,因此本组合物中使用中短链多不饱和脂肪酸;
膳食纤维优选水溶性膳食纤维fibersol-2、谷物燕麦膳食纤维和水果-柑橘纤维,经大量研究发现,此优化比例可有效控制空腹血糖、餐后血糖、糖化血红蛋白及脂类代谢紊乱,可以使血糖和尿糖含量降低,甚至可以减少治疗糖尿病所需药物的摄入;
松果菊苷可清除活性氧自由基,并调节Ⅱ型糖尿病患者的血脂代谢;总黄酮苷降低肾损伤指数和肌酐、尿素氮等肾功能指标,缓解肾损伤组织中还原型谷胱甘肽的消耗,并降低脂质过氧化标志物丙二醛的生成,从而减轻肾小球细胞坏死以及炎性浸润;原花青素对心肌组织具有保护作用,可改善心功能状态及心肌病理结构损伤,下调心肌组织NF-κB、TNF-α等因子的表达;芍药苷能够降低血糖水平、改善炎症反应、抑制NF-κB的核转,抑制炎症反应;
发明人经过大量的研究发现,萝卜硫苷能够减缓肝脏中的疾病症状,减弱葡萄糖的产生和葡萄糖的不耐受程度,其作用与甲福明二甲双胍(抗糖尿病药)十分相似;同时,萝卜硫苷能降低肥胖型糖尿病Ⅱ型患者的空腹血糖和血红蛋白数量,表明萝卜硫苷在治疗糖尿病方面有潜力;
生物素可明显改善肌糖原动员,利于肌肉糖代谢向正常化发展,改善糖耐量,本发明中的生物素含量是糖脂代谢关键基因正常表达和维持血糖和血脂稳态所必需的。
进一步地,蛋白质来源于浓缩乳清蛋白和/或大豆分离蛋白。
进一步地,碳水化合物来源于玉米淀粉、麦芽糊精、小麦粉、荞麦粉、青稞粉和燕麦粉中的一种或多种。
进一步地,脂肪为中短链不饱和脂肪酸,来源于椰子油、葵花籽油和亚麻籽油中的一种或多种。
进一步地,以膳食纤维的总重为基准,不溶性膳食纤维的含量为40%,可溶性膳食纤维的含量为30%,低聚果糖的含量为30%。
进一步地,可溶性膳食纤维为水溶性膳食纤维fibersol-2,不溶性膳食纤维为谷物燕麦膳食纤维及水果-柑橘纤维。
进一步地,以组合物的总重为基准,其他营养素各组分的含量为:松果菊苷0.001-0.002mg/g、总黄酮苷0.0004-0.0005mg/g、原花青素 0.002-0.003mg/g、芍药苷0.001-0.002mg/g、萝卜硫苷0.009-0.02mg/g、甘草酸0.0008-0.001mg/g、肌醇1-1.5mg/g和生物素0.004-0.006mg/g。
进一步地,总黄酮苷来源于淫羊藿和/或枳实。
进一步地,组合物由以下重量百分比的成分组成:蛋白质55%,碳水化合物15%,脂肪1%,膳食纤维25%,维生素、矿物质及其他营养素4%;其中,以组合物的总重为基准,其他营养素由松果菊苷0.0012mg/g、总黄酮苷0.00045mg/g、原花青素0.0026mg/g、芍药苷0.0011mg/g、萝卜硫苷 0.0099mg/g、甘草酸0.00086mg/g、肌醇1mg/g和生物素0.0045mg/g组成。
进一步地,以组合物的总重为基准,维生素的含量为:维生素A 0.02232μg/g、维生素E 0.00091μg/g、维生素B1 0.28mg/g、维生素B2 0.28 mg/g、维生素C 11.54mg/g、叶酸8.23mg/g、泛酸0.51mg/g、维生素D3 0.00551μg/g、β-胡萝卜素0.06826μg/g、维生素B60.28mg/g和维生素B12 0.28mg/g。
进一步地,以组合物的总重为基准,矿物质的含量为:镁7.28mg/g、硒0.32mg/g、铬0.88mg/g、锰0.1mg/g、铜0.04mg/g、钙17.62mg/g、铁 0.14mg/g、锌0.4mg/g。
进一步地,组合物的剂型为粉剂、颗粒剂、胶囊、片剂中的任一种。
本发明的营养素组合物还优化了其他营养素的成分和比例,在研究中意外发现,该营养素组合物干预能减缓正常个体体重增长趋势。原因可能为该组合物能够调节与食欲有关的胃肠激素酪酪肽(PYY)和胆囊收缩素(CCK) 的分泌,抑制食欲,增强饱腹感,延缓胃排空,从而减缓正常个体体重增长趋势。
本发明要求保护上述组合物在减缓体重增长中的应用。
本发明还要求保护上述组合物在减轻胰岛、肝脏、肾脏和心脑血管损伤中的应用。
借由上述方案,本发明至少具有以下优点:
(1)本发明选择合适的营养素作原料并优化其比例,来源丰富,食用安全,有良好的辅助降血糖功效,市场前景良好。
(2)本发明在补充营养的同时,能够在饮食干预过程中调控糖尿病人的血糖和血脂,稳定胰岛素水平并保护胰岛细胞组织,增加胰岛细胞数量,同时,长期食用本营养代餐包还能够保护肝肾功能。
(3)本发明的营养素组合物在稳定器官状态、减缓正常个体体重增长方面有明显效果,为其他产品的开发提供了启示。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例并配合详细附图说明如后。
附图说明
为了使本发明的内容更容易被清楚的理解,下面根据本发明的具体实施例并结合附图,对本发明作进一步详细的说明。
图1为空白组、模型组、阳性药组和营养素组合物1组大鼠的体重变化图;
图2为空白组、模型组、阳性药组和营养素组合物1组大鼠第4周的糖耐量测试结果;
图3为空白组、模型组、阳性药组和营养素组合物1组大鼠第12周的糖耐量测试结果;
图4为空白组、模型组、阳性药组、营养素组合物1组和营养素组合物 2组大鼠的胰岛形态观察结果。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
实施例
营养素组合物,由以下组分组成:蛋白质(浓缩乳清蛋白、大豆分离蛋白)50%、碳水化合物(玉米淀粉、小麦粉、燕麦粉)17%、脂肪(葵花籽油、亚麻籽油)1%,膳食纤维27%,维生素、矿物质和其他营养素5%。其中,
水溶性的膳食纤维fibersol-2、谷物燕麦膳食纤维和水果-柑橘纤维、低聚果糖分别占总膳食纤维的40%、30%和30%;
维生素A 0.02232μg/g、维生素E 0.00091μg/g、维生素B1 0.28mg/g、维生素B20.28mg/g、维生素C 11.54mg/g、叶酸8.23mg/g、泛酸0.51mg/g、维生素D3 0.00551μg/g、β-胡萝卜素0.06826μg/g、维生素B6 0.28mg/g和维生素B12 0.28mg/g;
镁7.28mg/g、硒0.32mg/g、铬0.88mg/g、锰0.1mg/g、铜0.04mg/g、钙17.62mg/g、铁0.14mg/g、锌0.4mg/g;
松果菊苷0.0012mg/g;总黄酮苷0.00045mg/g;原花青素0.0026mg/g;芍药苷0.0011mg/g;萝卜硫苷0.0099mg/g;甘草酸0.00086mg/g;肌醇1mg/g;生物素0.0045mg/g。
对比例
营养素组合物,由以下组分组成:蛋白质(浓缩乳清蛋白、大豆分离蛋白)15%、碳水化合物(玉米淀粉、小麦粉、燕麦粉)65%、脂肪(葵花籽油、亚麻籽油)5%,膳食纤维15%。其中,水溶性的膳食纤维fibersol-2、谷物燕麦膳食纤维和水果-柑橘纤维、低聚果糖分别占总膳食纤维的40%、 30%和30%。
动物实验
采用膳食诱导联合***注射的方法建立糖尿病大鼠模型。
1、实验动物处理
健康SD大鼠,雄性,体重210—230g,适应性饲养7d,禁食4h,测空腹血糖,按血糖水平分为空白组、模型组、阳性对照组及营养素组合物1 组(实施例)和营养素组合物2组(对比例),每组10只。空白组给予普通鼠维持饲料,其余组给予高热量饲料。4周后除空白组外,大鼠禁食12h (不禁水),腹腔注射***72h后,尾静脉取血测定大鼠空腹血糖值(测量前禁食12h)和随机血糖;空腹血糖值大于7.8mmol/L,且3-7天内测量随机血糖均大于16.7mmol/L,在此期间出现多饮、多尿症状的大鼠被选为糖尿病模型大鼠。
2、实验动物分组及干预方法
将造模后的糖尿病大鼠随机分为3组,即糖尿病组(DC组)、营养素组合物1组(DT1组)和营养素组合物2组(DT2组)。DC组继续饲喂高脂高糖饲料,DT1、DT2组饲喂含营养素组合物实例1、对比例的饲料(营养素组合物:高脂高糖饲料=1:1)。全部大鼠每周观察外形、体态、皮毛,测量一次体重、进食量和饮水量。
每周各组别大鼠的体重如表1所示,体重变化曲线如图1所示。
表1营养素组合物对大鼠体重的影响(x±s,g)(n=10)
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
从表1和图1可知,第2周***腹腔注射后,糖尿病大鼠出现前期体重上升,后期下降,体重极显著低于空白组大鼠(p<0.01),且体毛松散、毛色灰暗、活动减少,出现典型“三多一少”的糖尿病症状,结合血糖指标,说明造模成功。空白组实验期间体重持续增长。阳性药物组、营养素组合物 1组和2组的体重变化趋势与模型组一致,但不论是前期体重增加幅度、后期体重减少幅度,营养素组合物1组均小于模型组,并且大鼠体毛有光泽,接近正常大鼠,多饮、多食多尿状况得到明显改善,说明营养素组合物1组干预对糖尿病大鼠一般症状有显著改善作用。同时,营养素组合物干预还减缓了正常大鼠体重增长趋势。营养素组合物2组与模型组差异不显著。
3、空腹血糖测定
在饲养后第0、3、6、9、12周将大鼠禁食过夜(12h),于第二天上午9: 00用罗氏全活力型血糖仪测定尾静脉血糖值,将饲养前后各组大鼠的空腹血糖值与模型对照组进行比较分析。
4、糖耐量实验(OGTT)
称量大鼠空腹体重,按2g/Kg体重计算灌胃给予50%葡萄糖。分别于灌胃后0、10、20、30、60、90、120min测量大鼠尾部末梢血糖值并记录。
各组别大鼠第4周和第12周的空腹血糖及糖耐量结果如表2所示,第 4周灌胃后0、30、120min变化曲线如图2所示,第12周灌胃后0、30、120min 变化曲线如图3所示。
表2营养素组合物对大鼠空腹血糖及糖耐量的影响(x±s,mmol/L)(n=10)
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
从表2和图2、3可见,空白组大鼠的空腹血糖实验期间基本保持一个稳定水平,模型组及营养素组合物2组大鼠始终保持较高血糖水平,营养素组合物1组大鼠血糖水平随时间变化呈快速下降的趋势。与模型组相比,营营养素组合物1组大鼠餐后2小时血糖显著下降(p<0.05),到第12周时,血糖值降低了32.84%。营养素组合物1组干预处理,可降低空腹血糖峰值,并保持较稳定的血糖值。与模型组相比,营养素组合物1组的葡萄糖耐量曲线下面积显著低于模型组(p<0.05)。营养素组合物2组与模型组并无显著差异。以上结果表明,营养素组合物1组干预可显著降低糖尿病大鼠空腹血糖及餐后血糖峰值,平稳血糖。
5、组织、器官称重及保存
糖耐量实验结束后,将大鼠麻醉后脱颈椎处死,分离肝脏、肾脏、胰腺、脾脏、心脏,用生理盐水洗涤,滤纸吸干水分并称重,部分冻存于-80℃冰箱中。
6、糖代谢相关指标测定
(1)血清胰岛素、胰岛素敏感指数(ISI)和胰岛素抵抗指数(HOMA—IR)
饲喂12周后,将置于-80℃冰箱保存的大鼠血清取出,置于4℃冰箱中解冻,用胰岛素ELISA试剂盒测定大鼠血清胰岛素,操作按照试剂盒的使用说明进行。根据血清胰岛素和空腹血糖含量计算ISI和胰岛素抵抗指数。结果如表3所示。
组别 | 动物数(只) | 血清胰岛素 | 胰岛素抵抗指数 |
空白组 | 10 | 15.67±4.60 | 3.32±0.97 |
模型组 | 10 | 28.36±3.39** | 6.06±1.03** |
阳性药组 | 10 | 19.43±4.09<sup>aa</sup> | 4.35±0.96**<sup>aa</sup> |
营养素组合物1组 | 10 | 22.58±5.73**<sup>aa</sup> | 5.85±1.22**<sup>aa</sup> |
营养素组合物2组 | 10 | 27.98±4.23** | 6.02±1.54** |
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
从表3中可知,与空白组大鼠相比,模型组及营养素组合物2组组大鼠的血清胰岛素水平极显著升高(p<0.01),出现高胰岛素血症,血液中胰岛素含量高但血糖仍居高不下,说明糖尿病模型组大鼠胰岛素抵抗严重。营养素组合物1组干预12周后,与模型组相比,营养素组合物1组大鼠血清胰岛素水平降低25.60%接近正常大鼠水平。说明营养素组合物1组干预能较好的改善高胰岛素血症及胰岛素抵抗状态。
(2)糖化血红蛋白
饲喂12周后,将置于-80℃冰箱保存的大鼠血清取出,置于4℃冰箱中解冻,测定大鼠糖化血红蛋白结果如表4所示。
表4营养素组合物对大鼠糖化血红蛋白的影响——第12周(x±s,%)
组别 | 动物数(只) | 糖化血红蛋白(%) |
空白组 | 10 | 3.90±0.34 |
模型组 | 10 | 8.49±1.36** |
阳性药组 | 10 | 6.88±0.51**aa |
营养素组合物1组 | 10 | 7.27±0.48**aa |
营养素组合物2组 | 10 | 8.11±0.96** |
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
糖化血红蛋白是红细胞中的血红蛋白与血清中的糖类相结合的产物,可有效地反映在过去1~2个月内血糖平均值。表4中可见,12周营养素组合物1组干预组大鼠糖化血红蛋白极显著低于模型组(P<0.01)。表明营养素组合物1组干预可显著降低糖尿病大鼠平均血糖值。
(3)胰岛细胞计数及形态观察
胰腺固定、包埋、切片,进行免疫组化染色,按Point counting morphometry法计数胰岛β细胞。将胰腺组织用PBS缓释液冲洗,无菌条件下原代培养,光镜下观察两组胰岛细胞形态分100x,200x,400x倍数观察。观察结果如图4所示,其中,A为空白组,B为模型组,C为阳性药组, D为营养素组合物1组,E为营养素组合物2组。
胰腺是体内唯一分泌胰岛素的器官,胰腺的萎缩会影响胰腺分泌胰岛素的功能,引发血糖的升高。从图4中可知,与空白组大鼠相比,糖尿病模型组及营养素组合物2组大鼠胰腺出现明显变小、萎缩;营养素组合物1组干预12周后,糖尿病大鼠胰腺萎缩状况有所改善。空白组大鼠的胰岛细胞分布正常,胰岛呈椭圆形的细胞团,核圆形,胰岛界限清楚、胞浆丰富,无变性坏死;糖尿病模型组大鼠可见胰岛细胞皱缩、坏死,胰岛细胞数量显著减小,胞核呈溶解状,胞质疏松淡染;营养素组合物1组干预组大鼠可见胰岛界限较清晰,胰岛细胞分布正常,核圆形,胰岛细胞数量较糖尿病模型组大鼠丰富但仍显著少于空白组大鼠,胰岛细胞变性坏死程度有所减轻。
7、脂代谢相关指标测定
血清总胆固醇(TC)、血清甘油三酯(TG)、血清高密度脂蛋白胆固醇 (HDL-C)和血清低密度脂蛋白胆固醇(LDL-C)含量测定。结果如表5所示。
表5营养素组合对糖尿病大鼠血脂水平的影响(n=10)
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
从表5中可知,与糖尿病模型组相比,营养素组合物1组干预组大鼠的血清总胆固醇、甘油三酯、低密度脂蛋白水平均显著降低(p<0.05),营养素组合物1组干预后的糖尿病大鼠的血脂水平接近空白组大鼠(p>0.05)。表明营养素组合物1组具有较好的清除II型糖尿病大鼠胆固醇、甘油三酯、低密度脂蛋白的作用,并提高高密度脂蛋白胆固醇比值,纠正脂代谢紊乱,使糖尿病大鼠血脂水平逐步恢复到正常大鼠状态。营养素组合物2组与模型组无显著差异。结果提示营养素组合物1组对纠正II型糖尿病血脂代谢紊乱,预防或改善糖尿病的心脑血管并发症有积极的作用。
8、肝功能相关指标测定
谷丙转氨酶(ALT)、谷草转氨酶(AST)的测定,并计算肝系数。结果如表6。
表6营养素组合对大鼠肝脏功能的影响(n=10)
注:与空白组比,*P<0.05,**P<0.01;与模型组比,a P<0.05,aa P<0.01
根据表6中的结果可知,与糖尿病模型组相比,营养素组合物1组干预组大鼠的肝系数显著降低(p<0.05),说明营养素组合物1组干预可降低II型糖尿病大鼠肝肿大情况。此外,与糖尿病模型组相比,营养素组合物1组干预组能够极显著降低AST、ALT水平(p<0.01),显著提高AST/ALT值 (p<0.05)。可以看出,营养素组合物1组干预对II型糖尿病大鼠肝功能有明显的改善作用。营养素组合物2组与模型组相比无显著差异。说明营养素组合物1组干预能够逆转糖尿病大鼠肝功能紊乱,减轻肝细胞损伤,具有一定的保肝作用。
9、肾功能相关指标测定
尿微量白蛋白的测定,结果如表7所示。
表7营养素组合对大鼠尿微量白蛋白的影响(n=10)
根据表7中的结果可知,与糖尿病模型组相比,营养素组合物1组干预组大鼠的尿微量白蛋白显著降低(p<0.05),说明营养素组合物1组干预能够减轻肾脏损伤,具有一定的保肾作用。营养素组合物2组与模型组相比无显著差异。
显然,上述实施例仅仅是为清楚地说明所作的举例,并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种辅助降血糖的营养素组合物,其特征在于,所述组合物由以下重量百分比的成分组成:蛋白质50-60%,碳水化合物10-20%,脂肪0.5-1.5%,膳食纤维20-30%,维生素、矿物质及其他营养素3-5%;其中,
所述膳食纤维为不溶性膳食纤维、可溶性膳食纤维和低聚果糖的组合;
所述维生素为维生素A、维生素E、维生素B1、维生素B2、维生素C、叶酸、泛酸、维生素D3、β-胡萝卜素、维生素B6和维生素B12的组合;
所述矿物质为镁、硒、铬、锰、铜、钙、铁和锌的组合;
所述其他营养素为松果菊苷、总黄酮苷、原花青素、芍药苷、萝卜硫苷、甘草酸、肌醇和生物素的组合。
2.根据权利要求1所述的组合物,其特征在于:所述脂肪为中短链不饱和脂肪酸,来源于椰子油、葵花籽油和亚麻籽油中的一种或多种。
3.根据权利要求1所述的组合物,其特征在于:以膳食纤维的总重为基准,不溶性膳食纤维的含量为30-50%,可溶性膳食纤维的含量为20-40%,低聚果糖的含量为20-40%。
4.根据权利要求1所述的组合物,其特征在于:所述可溶性膳食纤维为水溶性膳食纤维fibersol-2,不溶性膳食纤维选自谷物燕麦膳食纤维和/或水果-柑橘纤维。
5.根据权利要求1所述的组合物,其特征在于,以组合物的总重为基准,所述其他营养素各组分的含量为:松果菊苷0.001-0.002mg/g、总黄酮苷0.0004-0.0005mg/g、原花青素0.002-0.003mg/g、芍药苷0.001-0.002mg/g、萝卜硫苷0.009-0.02mg/g、甘草酸0.0008-0.001mg/g、肌醇1-1.5mg/g和生物素0.004-0.006mg/g。
6.根据权利要求1所述的组合物,其特征在于:所述总黄酮苷来源于淫羊藿和/或枳实。
7.根据权利要求1所述的组合物,其特征在于:所述组合物由以下重量百分比的成分组成:蛋白质55%,碳水化合物15%,脂肪1%,膳食纤维25%,维生素、矿物质及其他营养素4%;其中,以组合物的总重为基准,其他营养素由松果菊苷0.0012mg/g、总黄酮苷0.00045mg/g、原花青素0.0026mg/g、芍药苷0.0011mg/g、萝卜硫苷0.0099mg/g、甘草酸0.00086mg/g、肌醇1mg/g和生物素0.0045mg/g组成。
8.根据权利要求7所述的组合物,其特征在于:以组合物的总重为基准,维生素的含量为:维生素A 0.02232μg/g、维生素E 0.00091μg/g、维生素B1 0.28mg/g、维生素B2 0.28mg/g、维生素C 11.54mg/g、叶酸8.23mg/g、泛酸0.51mg/g、维生素D3 0.00551μg/g、β-胡萝卜素0.06826μg/g、维生素B6 0.28mg/g和维生素B12 0.28mg/g;
以组合物的总重为基准,矿物质的含量为:镁7.28mg/g、硒0.32mg/g、铬0.88mg/g、锰0.1mg/g、铜0.04mg/g、钙17.62mg/g、铁0.14mg/g、锌0.4mg/g。
9.一种权利要求1-8任一项所述的组合物在减缓体重增长中的应用。
10.一种权利要求1-8任一项所述的组合物在减轻胰岛、肝脏、肾脏和心脑血管损伤中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110343293.3A CN112841637A (zh) | 2021-03-30 | 2021-03-30 | 一种辅助降血糖的营养素组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110343293.3A CN112841637A (zh) | 2021-03-30 | 2021-03-30 | 一种辅助降血糖的营养素组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112841637A true CN112841637A (zh) | 2021-05-28 |
Family
ID=75993264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110343293.3A Pending CN112841637A (zh) | 2021-03-30 | 2021-03-30 | 一种辅助降血糖的营养素组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112841637A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TH60406A (th) * | 2002-09-06 | 2004-01-16 | นางดารานีย์ วัจนะวุฒิวงศ์ | องค์ประกอบทางโภชนาการสำหรับควบคุมระดับน้ำตาลในเลือด |
CN104286849A (zh) * | 2014-09-26 | 2015-01-21 | 上海励成营养产品科技股份有限公司 | 一种糖尿病专用型肠内营养多聚合剂 |
CN110326780A (zh) * | 2019-07-18 | 2019-10-15 | 成都三勒浆药业集团四川华美制药有限公司 | 一种具有降血糖功能的营养代餐及其制备方法 |
CN111418833A (zh) * | 2020-04-08 | 2020-07-17 | 河北三元食品有限公司 | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 |
-
2021
- 2021-03-30 CN CN202110343293.3A patent/CN112841637A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TH60406A (th) * | 2002-09-06 | 2004-01-16 | นางดารานีย์ วัจนะวุฒิวงศ์ | องค์ประกอบทางโภชนาการสำหรับควบคุมระดับน้ำตาลในเลือด |
CN104286849A (zh) * | 2014-09-26 | 2015-01-21 | 上海励成营养产品科技股份有限公司 | 一种糖尿病专用型肠内营养多聚合剂 |
CN110326780A (zh) * | 2019-07-18 | 2019-10-15 | 成都三勒浆药业集团四川华美制药有限公司 | 一种具有降血糖功能的营养代餐及其制备方法 |
CN111418833A (zh) * | 2020-04-08 | 2020-07-17 | 河北三元食品有限公司 | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 |
Non-Patent Citations (5)
Title |
---|
丁玉峰等: "《儿科药物手册》", 31 October 1999, 湖北科学技术出版社 * |
丁芳林: "《食品化学》", 31 January 2017, 华中科技大学电子音像出版社 * |
孔令义: "《天然药物化学》", 31 December 2019, 中国医药科技出版社 * |
安利日用品有限公司: "《养藏善衡》", 31 July 2015, 广东人民出版社 * |
龚仆: "《图解糖尿病饮食宜忌大百科》", 31 May 2014, 福建科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11259555B2 (en) | Specialized flour for nutrition meals for diabetes and preparation method and use thereof | |
CN100579395C (zh) | 一种具有稳定餐后血糖的方便营养粥及其制备方法 | |
CN109511851A (zh) | 一种降低食物升糖指数的餐前固体饮料及其制备方法 | |
CN108095113A (zh) | 一种具有减脂降糖作用的组合物、制剂及其应用 | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN100584215C (zh) | 一种具有稳定餐后血糖的保健米及其制备方法 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
CN112369577A (zh) | 一种阻糖美容组合物及其制备方法 | |
CN107692222A (zh) | 一种降血糖的中药食疗代餐品 | |
CN114651982A (zh) | 一种具有可延缓餐后血糖的组合物及其制备方法及其应用 | |
AU2015354844B2 (en) | Composition comprising a pentose and polyphenolic compound | |
CN105613882A (zh) | 黑青稞降糖茶(奶茶) | |
CN112841637A (zh) | 一种辅助降血糖的营养素组合物 | |
CN111602760A (zh) | 一种糖尿病非药物干预膳食营养调理食品 | |
LU501117B1 (en) | Nutritional Grain Meal Replacement Powder Of Burdock And Preparation Method Thereof | |
CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
KR20130089361A (ko) | 당뇨병 개선을 위한 혈당 저하 및 조절용 조성물 | |
KR20090081062A (ko) | 당뇨병 예방 치료 및 내장 기능 치료제 조성물과 그 제조방법 | |
CN114451560A (zh) | 一种糖尿病患者用膳食组合物及其应用 | |
CN114532544A (zh) | 降糖、控糖的谷果植物肽固体饮料 | |
US7416750B1 (en) | Composition to provide maintenance and nutritional support in glycemic control deficits | |
CN110101020A (zh) | 一种糖尿病全营养素配方食品 | |
JP2006020606A (ja) | 肥満防止、改善のための健康食品用組成物 | |
CN107836707B (zh) | 一种具有改善糖脂代谢紊乱的健康食品基料的制备方法及应用 | |
KR20150044014A (ko) | 소화흡수를 억제하는 항비만용 추출물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210528 |
|
RJ01 | Rejection of invention patent application after publication |